According to findings from a new systematic review and meta-analysis, a probiotic called VSL#3 may be effective in inducing remission in active ulcerative colitis (UC), but it has not been found to be effective in treating active Crohn’s disease (CD) or preventing relapse after its remission.The original article by Y. Derwa et al. was a technically checked by Dr Y Yuan and the Handling Editor for this article was Professor Jonathan Rhodes, and it was accepted for publication after full peer-review.
Ulcerative colitis (UC) and Crohn’s disease (CD) are inflammatory bowel diseases (IBD). Evidence implicates disturbances of the gastrointestinal microbiota in their pathogenesis.
It was concluded that probiotic VSL#3 may be effective in inducing remission in active ulcerative colitis (UC). Probiotics may be as effective as 5-ASAs in preventing relapse of quiescent ulcerative colitis (UC). The efficacy of probiotics in Crohn’s disease (CD) remains uncertain, and more evidence from RCTs is required before their utility is known. Therefore use of probiotics and other “microflora-altering products” to manipulate the gut microbiome holds promise for preventing and treating mild forms of inflammatory and metabolic disorders, but “a rational development” of these products that includes in-depth research into their protective mechanisms is needed,
Read the full article click on the link : http://bit.ly/2tO8Nvw